These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 37507719)

  • 21. Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.
    McNamara RP; Maron JS; Boucau J; Roy V; Webb NE; Bertera HL; Barczak AK; Positives Study Staff T; Franko N; Logue JK; Kemp M; Li JZ; Zhou L; Hsieh CL; McLellan JS; Siedner MJ; Seaman MS; Lemieux JE; Chu HY; Alter G
    mBio; 2023 Aug; 14(4):e0090223. PubMed ID: 37535402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity.
    Sasaki M; Toba S; Itakura Y; Chambaro HM; Kishimoto M; Tabata K; Intaruck K; Uemura K; Sanaki T; Sato A; Hall WW; Orba Y; Sawa H
    mBio; 2021 Aug; 12(4):e0141521. PubMed ID: 34425707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance.
    Lista MJ; Winstone H; Wilson HD; Dyer A; Pickering S; Galao RP; De Lorenzo G; Cowton VM; Furnon W; Suarez N; Orton R; Palmarini M; Patel AH; Snell L; Nebbia G; Swanson C; Neil SJD
    J Virol; 2022 Dec; 96(23):e0125022. PubMed ID: 36350154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters.
    Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM
    J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Landscape of T cell epitopes displays hot mutations of SARS-CoV-2 variant spikes evading cellular immunity.
    Gan M; Cao J; Zhang Y; Fu H; Lin X; Ouyang Q; Xu X; Yuan Y; Fan X
    J Med Virol; 2024 Feb; 96(2):e29452. PubMed ID: 38314852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters.
    Plunkard J; Mulka K; Zhou R; Tarwater P; Zhong W; Lowman M; Wong A; Pekosz A; Villano J
    mBio; 2023 Apr; 14(2):e0007823. PubMed ID: 37036339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta-containing bivalent SARS-CoV-2 protein vaccine elicits durable broad neutralization in macaques and protection in hamsters.
    Berry C; Pavot V; Anosova NG; Kishko M; Li L; Tibbitts T; Raillard A; Gautheron S; Cummings S; Bangari DS; Kar S; Atyeo C; Deng Y; Alter G; Gutzeit C; Koutsoukos M; Chicz RM; Lecouturier V
    Commun Med (Lond); 2023 May; 3(1):75. PubMed ID: 37237062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covid-19 variants: Impact on transmissibility and virulence.
    Malik YA
    Malays J Pathol; 2022 Dec; 44(3):387-396. PubMed ID: 36591708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.
    Hsieh M-S; Hsu C-W; Liao H-C; Lin C-L; Chiang C-Y; Chen M-Y; Liu S-J; Liao C-L; Chen H-W
    J Virol; 2024 Feb; 98(2):e0154623. PubMed ID: 38299865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents.
    Garcia-Valtanen P; Hope CM; Masavuli MG; Yeow AEL; Balachandran H; Mekonnen ZA; Al-Delfi Z; Abayasingam A; Agapiou D; Stella AO; Aggarwal A; Bouras G; Gummow J; Ferguson C; O'Connor S; McCartney EM; Lynn DJ; Maddern G; Gowans EJ; Reddi BAJ; Shaw D; Kok-Lim C; Beard MR; Weiskopf D; Sette A; Turville SG; Bull RA; Barry SC; Grubor-Bauk B
    Cell Rep Med; 2022 Jun; 3(6):100651. PubMed ID: 35654046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
    Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters.
    Mohandas S; Yadav PD; Shete A; Nyayanit D; Jain R; Sapkal G; Mote C
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern.
    Facciuolo A; Van Kessel J; Kroeker A; Liao M; Lew JM; Falzarano D; Kelvin AA; Gerdts V; Napper S
    Front Microbiol; 2023; 14():1148255. PubMed ID: 37065160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergency SARS-CoV-2 Variants of Concern: Novel Multiplex Real-Time RT-PCR Assay for Rapid Detection and Surveillance.
    Chung HY; Jian MJ; Chang CK; Lin JC; Yeh KM; Chen CW; Hsieh SS; Hung KS; Tang SH; Perng CL; Chang FY; Wang CH; Shang HS
    Microbiol Spectr; 2022 Feb; 10(1):e0251321. PubMed ID: 35196812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.